Please login to the form below
Dr Michael Mehler joins leon-nanodrugs as CEO
He succeeds Dr Ted Odlaug
Munich-headquartered leon-nanodrugs has appointed Dr Michael Mehler as chief executive officer, succeeding Dr Ted Odlaug who moves to the supervisory board.
Dr Mehler brings over 25 years of leadership experience in the pharma and biotech industries, most recently as chief executive of SpePharm, a Switz specialty hospital products developer.
Prior to this, he was chief executive officer of Riemser Pharma, and held a number of positions at Actelion Pharmaceuticals, Merck & Co and Novartis.
Dr Hubert Birner, chairman of the leon-nanodrugs board, said: “We welcome Michael to lead leon nanodrugs on our joint journey to continued growth and internationalisation.
“We know Michael as a very experienced executive and look forward to working with him.
“We would also like to express our sincere appreciation to Ted who did a tremendously impressing job - he will obviously bring his valuable expertise to the board in his new role and continue to complement our management team.”
Featured jobs
-
Account Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
- Global Business Development Director – Health Education
-
excellent commission
-
Business Director
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- GSK upbeat on its return to oncology market
- BMS and Celgene deal sparks debate on pharma profit motive, more M&A
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- The UK’s new five-year pricing agreement
- Lucid kick-starts 2019 with spellbinding new additions to its writing and account teams
- New hires at Nanoform, Leo Pharma and Calliditas
- Page & Page welcomes Clare Bates to the team
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
GK Strategy
GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....
Latest intelligence
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- ...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again – in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
